TG Therapeutics, Inc. (TGTX) Analysts See $-0.46 EPS on May, 4

May 3, 2018 - By Joshua Cleveland

Big Money Sentiment increased to 2 in 2017 Q4. It has change of 0.79, from 2017Q3’s 1.21. The ratio is positive due to TG Therapeutics, Inc. positioning: 12 sold and 14 reduced. 17 funds took holdings and 35 increased holdings. Investors holded 35.13 million in 2017Q3 but now own 35.20 million shares or 0.20% more.
California State Teachers Retirement System accumulated 80,941 shs or 0% of the stock. Gam Holdings Ag stated it has 98,600 shs. Voya Investment Management Limited Liability Corp has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 22,521 shs. Moreover, Bb&T Securities Ltd Liability has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). Deutsche Natl Bank Ag holds 0% of its capital in TG Therapeutics, Inc. (NASDAQ:TGTX) for 117,990 shs. Pnc Services stated it has 600 shs. California Pub Employees Retirement Systems has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). The Nebraska-based Ameritas Invest has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). State Of Wisconsin Inv Board accumulated 41,000 shs. Geode Mgmt Ltd Company accumulated 0% or 462,270 shs. Victory Cap owns 3,056 shs. Rhumbline Advisers reported 44,672 shs or 0% of all its holdings. Citigroup owns 129,251 shs for 0% of their capital. Royal Natl Bank Of Canada holds 0% in TG Therapeutics, Inc. (NASDAQ:TGTX) or 14,027 shs. Teacher Retirement Sys Of Texas owns 18,417 shs.

TG Therapeutics, Inc. registered $272,051 net activity with 0 insider purchases and 1 insider sale since December 29, 2017.

TG Therapeutics, Inc. (NASDAQ:TGTX)’s earnings report is expected on May, 4., as reported by Faxor. Analysts have anticipation on stock’s earnings per share of $-0.46. That’s up 11.54 % from last year’s $-0.52 earnings per share. Wall Street predicts 0.00 % EPS growth as of May, 4. The stock decreased 1.05% or $0.15 during the last trading session, hitting $14.1.Currently TG Therapeutics, Inc. is uptrending after 23.61% change in last May 3, 2017. TGTX has also 628,616 shares volume. The stock outperformed the S&P500 by 12.06%.

TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage

In total 4 analysts cover TG Therapeutics (NASDAQ:TGTX). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 11 are the (NASDAQ:TGTX)’s analyst reports since November 14, 2017 according to StockzIntelligence Inc. In Wednesday, January 17 report FBR Capital maintained the stock with “Buy” rating. On Thursday, April 19 Raymond James maintained the shares of TGTX in report with “Buy” rating. On Monday, December 11 the stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given by FBR Capital. On Friday, December 1 the firm has “Buy” rating given by B. Riley & Co. On Monday, December 11 the stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given by H.C. Wainwright. On Wednesday, March 21 H.C. Wainwright initiated TG Therapeutics, Inc. (NASDAQ:TGTX) rating. H.C. Wainwright has “Buy” rating and $38.0 target. On Tuesday, November 14 H.C. Wainwright reinitiated TG Therapeutics, Inc. (NASDAQ:TGTX) with “Buy” rating. The stock rating was maintained by FBR Capital with “Buy” on Friday, March 9. On Friday, February 2 the rating was maintained by FBR Capital with “Buy”.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States.The firm is worth $1.03 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia.Currently it has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.